Article

Osimertinib tolerance in a patient with Stevens Johnson Syndrome during Osimertinib treatment followed by Pembrolizumab

2023-09-14

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> Osimertinib has emerged as an important tool in the treatment of non-small cell lung cancers (NSCLC) with certain activating mutations of epidermal growth factor receptor (EGFR). However, Osimertinib may cause adverse effects, including severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). The ris...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3b482a83-7e3e-565a-a633-bac4b91d11e4
DOI: 10.21203/rs.3.rs-3293546/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Osimertinib tolerance in a patient with Stevens Johnson Syndrome during Osimertinib treatment followed by PembrolizumabDOI 10.21203/rs.3.rs-3293546/v1Read

Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation-A Case Report and a Review of the Literature.Semantic proximity Read

Osimertinib-Induced Toxic Epidermal Necrolysis - A Case Report.Semantic proximity Read

Class I HLA Alleles Are Associated With an Increased Risk of Osimertinib-Induced Hypersensitivity.Semantic proximity Read

Biologic Treatment for Cutaneous Immune-Related Adverse Events in Cancer Patients Undergoing Immune-Checkpoint Therapy: A Retrospective ReviewSemantic proximity Read

Adverse Events in Osimertinib Treatment for EGFR-Mutated Non-Small-Cell Lung Cancer: Unveiling Rare Life-Threatening Myelosuppression.Semantic proximity Read

A retrospective analysis of drugs associated with the development of cutaneous squamous cell carcinoma reported by patients on the FDA’s adverse events reporting systemSemantic proximity Read

Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort studySemantic proximity Read

Prediction and treatment of skin adverse reactions related to inhibitors at immune checkpointsSemantic proximity Read

Retreatment With Osimertinib Following Pneumonitis.Semantic proximity Read

Impact of prophylactic skin toxicity management on treatment continuity and clinical outcomes in EGFR-mutant non-small cell lung cancer treated with osimertinib: a 7-year real-world retrospective cohort study.Semantic proximity Read

Successful desensitization under antihistamine suppression in a case with urticaria due to osimertinib.Semantic proximity Read

Successful administration of low-dose almonertinib in a patient with lung adenocarcinoma after osimertinib-induced interstitial lung disease: a case report and literature review.Semantic proximity Read